{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T06:34:38Z","timestamp":1783233278169,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AG070849"],"award-info":[{"award-number":["R01AG070849"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R03AG083207"],"award-info":[{"award-number":["R03AG083207"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cct.2025.107814","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:06:47Z","timestamp":1738897607000},"page":"107814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Disease progression trajectory curves to estimate saved time in Alzheimer's disease trials"],"prefix":"10.1016","volume":"151","author":[{"given":"Guogen","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.cct.2025.107814_bb0005","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cct.2025.107814_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2025.107814_bb0015","article-title":"Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer\u2019s dis- ease: open peer commentary","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimer\u2019s Dementia Transl. Rese. Clin. Interventions."},{"issue":"6","key":"10.1016\/j.cct.2025.107814_bb0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cct.2025.107814_bb0025","article-title":"Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer\u2019s disease","volume":"8","author":"Wang","year":"2022","journal-title":"Alzheimer\u2019s Dementia Transl. Rese. Clin. Interventions."},{"issue":"4","key":"10.1016\/j.cct.2025.107814_bb0030","first-page":"1","article-title":"A combined measure of cognition and function for clinical trials: the integrated Alzheimer\u2019s disease rating scale (IADRS)","volume":"2","author":"Wessels","year":"2015","journal-title":"J. Prev Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.cct.2025.107814_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/ADR-230043","article-title":"ADSS: a composite score to detect disease progression in Alzheimer\u2019s disease","volume":"8","author":"Shan","year":"2024","journal-title":"J. Alzheimer\u2019s Disease Rep."},{"issue":"9","key":"10.1016\/j.cct.2025.107814_bb0040","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2025.107814_bb0045","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019s & Dementia Transl. Res. Clin. Intervent."},{"issue":"2","key":"10.1016\/j.cct.2025.107814_bb0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jalz.2010.03.018","article-title":"Disease progression model for cognitive deterioration from Alzheimer\u2019s disease neuroimaging initiative database","volume":"7","author":"Ito","year":"2011","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"21","key":"10.1016\/j.cct.2025.107814_bb0055","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1002\/sim.7811","article-title":"A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer\u2019s disease","volume":"37","author":"Wang","year":"2018","journal-title":"Stat. Med."},{"issue":"28","key":"10.1016\/j.cct.2025.107814_bb0060","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1002\/sim.9581","article-title":"Progression models for repeated measures: estimating novel treatment effects in progressive diseases","volume":"41","author":"Raket","year":"2022","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.cct.2025.107814_bb0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.14283\/jpad.2023.50","article-title":"\u2018Time saved\u2019 as a demonstration of clinical meaningfulness and illustrated using the Donanemab TRAILBLAZER-ALZ study findings","volume":"10","author":"Dickson","year":"2023","journal-title":"J. Prevent. Alzheimer\u2019s Dis."},{"issue":"6","key":"10.1016\/j.cct.2025.107814_bb0070","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.cct.2025.107814_bb0075","series-title":"Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The role of biomarkers in alzheimer\u2019s disease drug development","volume":"vol. 1118","author":"Cummings","year":"2019"},{"issue":"2","key":"10.1016\/j.cct.2025.107814_bb0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.trci.2015.06.005","article-title":"Alzheimer\u2019s disease progression model using disability assessment for dementia scores from bapineuzumab trials","volume":"1","author":"Xu","year":"2015","journal-title":"Alzheimer\u2019s Dementia Transl. Rese. Clin. Interventions."},{"key":"10.1016\/j.cct.2025.107814_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.trci.2018.04.006","article-title":"Statistical advances in clinical trials and clinical research","volume":"4","author":"Shan","year":"2018","journal-title":"Alzheimer\u2019s & Dementia Transl. Res. Clin. Intervent."},{"issue":"4","key":"10.1016\/j.cct.2025.107814_bb0090","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jalz.2018.12.008","article-title":"Staging biomarkers in preclinical autosomal dominant Alzheimer\u2019s disease by estimated years to symptom onset","volume":"15","author":"Wang","year":"2019","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"22","key":"10.1016\/j.cct.2025.107814_bb0095","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cct.2025.107814_bb0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/biostatistics\/kxt050","article-title":"Predicting the restricted mean event time with the subject\u2019s baseline covariates in survival analysis","volume":"15","author":"Tian","year":"2014","journal-title":"Biostatistics"},{"key":"10.1016\/j.cct.2025.107814_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100732","article-title":"Optimal two-stage designs based on restricted mean survival time for a single-arm study","volume":"21","author":"Shan","year":"2021","journal-title":"Contemp. Clin. Trials Commun."},{"issue":"5","key":"10.1016\/j.cct.2025.107814_bb0110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","article-title":"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cct.2025.107814_bb0115","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.1016\/j.conctc.2022.100988","article-title":"Effects of dose change on the success of clinical trials","author":"Shan","year":"2022","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.cct.2025.107814_bb0120","series-title":"Vignette for survRM2 Package: Comparing Two Survival Curves Using the Restricted Mean Survival Time","author":"Uno","year":"2017"},{"key":"10.1016\/j.cct.2025.107814_bb0125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12874-019-0696-x","article-title":"Two-stage optimal designs with survival endpoint when the follow-up time is restricted","volume":"19","author":"Shan","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"issue":"18","key":"10.1016\/j.cct.2025.107814_bb0130","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.cct.2025.107814_bb0135","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","article-title":"The global deterioration scale for assessment of primary degenerative dementia","volume":"139","author":"Reisberg","year":"1982","journal-title":"Am. J. Psychiatry"},{"issue":"26","key":"10.1016\/j.cct.2025.107814_bb0140","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1002\/sim.8699","article-title":"Restricted mean survival time for interval-censored data","volume":"39","author":"Zhang","year":"2020","journal-title":"Stat. Med."},{"issue":"10","key":"10.1016\/j.cct.2025.107814_bb0145","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1177\/0962280220913971","article-title":"Accurate confidence intervals for proportion in studies with clustered binary outcome","volume":"29","author":"Shan","year":"2020","journal-title":"Stat. Methods Med. Res."},{"issue":"3","key":"10.1016\/j.cct.2025.107814_bb0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.14283\/jpad.2024.64","article-title":"\u201cTime saved\u201d calculations to improve decision-making in progressive disease studies","volume":"11","author":"Dickson","year":"2024","journal-title":"J. Prev Alzheimers Dis."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:36:43Z","timestamp":1760787403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"alternative-id":["S1551714425000084"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.107814","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease progression trajectory curves to estimate saved time in Alzheimer's disease trials","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.107814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107814"}}